[1] Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study. JAMA Oncol, 2018 Sep 27. [Epub ahead of print]
[2] Flemming JA, Terrault NA. Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B: One of these things is not like the other. JAMA Oncol, 2018 Sep 27. [Epub ahead of print]
[3] Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol,2011,54:12-18.
[4] Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology,2017,66:335-343.
[5] Hou J, Zhao W, Lee C, et al. Prospective, randomized assessment of hbv-associated and other clinical outcome events during long-term therapy with entecavir or other hbv nucleos(t)ide analogues in patients with chronic HBV infection. Hepatology,2017,66(Suppl.S1):12A-13A.
[6] 中华医学会肝病学分会. 中华医学会肝病学分会关于保持学术独立和学术公正的倡议. 肝脏,2008,13:185. |
